When conservative management fails to adequately control your patients’ NVP, prescribe Bonjesta®

Bonjesta logo

A new formulation of DICLEGIS®

Bonjesta® is indicated for the treatment of NVP when conservative management fails
  • Bonjesta® received FDA approval in November 2016, based on safety and efficacy data from Diclegis® (doxylamine succinate and pyridoxine hydrochloride) and two clinical bioequivalence studies and a food effect trial.
  • Like Diclegis®, Bonjesta® is indicated for the treatment of NVP in women who do not respond to conservative management.
  • Same active ingredients in the same proportion:
    • Doxylamine succinate (an antihistamine)
    • Pyridoxine hydrochloride (vitamin B6)
  • Bonjesta® has not been studied in women with hyperemesis gravidarum. The safety and effectiveness of Bonjesta® has not been studied in children 18 and under.

The combination of doxylamine succinate and pyridoxine hydrochloride in Bonjesta® is recommended by ACOG as first-line pharmacotherapy for nausea and vomiting of pregnancy (NVP) when conservative management fails.1

Bonjesta® is a multilayer, extended-release tablet designed to provide both fast-acting and long-lasting symptom relief: 

Pill schema

Bonjesta®’s extended-release tablets deliver a total of 20 mg doxylamine succinate and 20 mg pyridoxine hydrochloride.

Learn more about Bonjesta®’s safety and efficacy

Prescribing Bonjesta®

In order to achieve the steady-state concentration for optimal control of NVP, Bonjesta® should be taken as a daily prescription, not PRN.

Day 1

The patient takes one Bonjesta® tablet orally at bedtime.

Day 2

If symptoms persist the following day, the patient should increase her daily dose to:

  • One tablet in the morning
  • One tablet at bedtime

The maximum recommended daily dose of Bonjesta® is two tablets per day.

Administering Bonjesta®

  • Bonjesta® should be taken on an empty stomach with a glass of water
  • Tablets should be swallowed whole and should not be crushed, chewed or split


  1. ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. Obstet Gynecol 2018;131(1):e15-30.

Ordering Samples

Help your patients get started on Bonjesta® today!

Each physician sample bottle contains 6 tablets of Bonjesta® and patient information.

Due to unusually high demand, we are temporarily out of samples. Please submit your sample request and we will ship your samples as soon as they become available.

Click here to download and print the sample order form

Indication and important safety information


Bonjesta® is a fixed-dose combination drug product of 20 mg doxylamine succinate, an antihistamine, and 20 mg pyridoxine hydrochloride, a vitamin B6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.


Bonjesta® has not been studied in women with hyperemesis gravidarum.


Contraindications: Bonjesta® is contraindicated in women with any of the following conditions:

  • Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation;
  • Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of Bonjesta®.

Warnings and Precautions:

  • Somnolence: Bonjesta® may cause somnolence due to the anticholinergic properties of doxylamine succinate, an antihistamine. Women should avoid engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery, while using Bonjesta® until cleared to do so by their healthcare provider.
  • Central nervous system (CNS) depressants: Use of Bonjesta® is not recommended if a woman is concurrently using CNS depressants, such as alcohol or sedating medications, including other antihistamines (present in some cough and cold medications), opiates, and sleep aids. The combination of Bonjesta® and CNS depressants could result in severe drowsiness leading to falls or other accidents.
  • Concomitant Medical Conditions: Use Bonjesta® with caution in women with (1) asthma, (2) increased intraocular pressure, (3) narrow angle glaucoma, (4) a stenosing peptic ulcer, (5) pyloroduodenal obstruction, or (6) bladder-neck obstruction.
  • Interference with Urine Screen for Methadone, Opiates and Phencyclidine Phosphate (PCP): There have been reports of false positive urine screening tests for methadone, opiates, and PCP with doxylamine succinate/pyridoxine hydrochloride use. Women should be informed that use of Bonjesta® may result in false positive urine drug screening for methadone, opiates and PCP.

Adverse Reactions: The most common adverse reaction (≥5 percent and exceeding the rate in placebo) with combination 10 mg doxylamine succinate and 10 mg pyridoxine hydrochloride tablets is somnolence.

Drug-Food Interactions: A food-effect trial demonstrated that the delay in the onset of action of Bonjesta® may be further delayed, and a reduction in absorption may occur when tablets are taken with food. Therefore, Bonjesta® should be taken on an empty stomach with a glass of water.

Use in Specific Populations:

  • Pregnancy: Bonjesta® is intended for use in pregnant women. 
  • Lactation: Women should not breastfeed while using Bonjesta® because the antihistamine component (doxylamine succinate) in Bonjesta® can pass into breast milk. Excitement, irritability, and sedation have been reported in nursing infants presumably exposed to doxylamine succinate through breast milk. Infants with apnea or other respiratory syndromes may be particularly vulnerable to the sedative effects of Bonjesta® resulting in worsening of their apnea or respiratory conditions.
  • Pediatric Use: The safety and effectiveness of Bonjesta® in children under 18 years of age have not been established. Fatalities have been reported from doxylamine overdose in children. Children appear to be at a high risk for cardiorespiratory arrest.

Overdosage: Bonjesta® is an extended-release formulation; therefore, signs and symptoms of intoxication may not be apparent immediately. Signs and symptoms of overdose may include restlessness, dryness of mouth, dilated pupils, sleepiness, vertigo, mental confusion, and tachycardia. At toxic doses, doxylamine exhibits anticholinergic effects, including seizures, rhabdomyolysis, acute renal failure and death. If treatment is needed, it consists of gastric lavage or activated charcoal, whole bowel irrigation and symptomatic treatment. If you suspect an overdose or seek additional information about overdose treatment, call a poison control center at 1-800-222-1222.

To report suspected adverse reactions, contact Duchesnay Inc. at 1-855-722-7734 or medicalinfo@duchesnayusa.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Select a style